About: Avian reovirus sigma C enhances the mucosal and systemic immune responses elicited by antigen-conjugated lactic acid bacteria

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Avian reovirus sigma C enhances the mucosal and systemic immune responses elicited by antigen-conjugated lactic acid bacteria Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Avian reovirus sigma C enhances the mucosal and systemic immune responses elicited by antigen-conjugated lactic acid bacteria
Creator	Lin, Chuen-Fu Chang, Tien-Jye Chen, Jeng-Rung Hsu, Ai-Ping Hsu, Wei-Li Liao, Jiunn-Wang Lin, Kuan-Hsun Shien, Jui-Hung
Source	Elsevier; Medline; PMC
abstract	Abstract Mucosal surfaces are common sites of pathogen colonization/entry. Effective mucosal immunity by vaccination should provide protection at this primary infection site. Our aim was to develop a new vaccination strategy that elicits a mucosal immune response. A new strain of Enterococcus faecium, a non pathogenic lactic acid bacteria (LAB) with strong cell adhesion ability, was identified and used as a vaccine vector to deliver two model antigens. Specifically, sigma (σ) C protein of avian reovirus (ARV), a functional homolog of mammalian reovirus σ1 protein and responsible for M-cell targeting, was administered together with a subfragment of the spike protein of infectious bronchitis virus (IBV). Next, the effect of immunization route on the immune response was assessed by delivering the antigens via the LAB strain. Intranasal (IN) immunization induced stronger humoral responses than intragastic (IG) immunization. IN immunization produced antigen specific IgA both systemically and in the lungs. A higher IgA titer was induced by the LAB with ARV σC protein attached. Moreover, the serum of mice immunized with LAB displaying divalent antigens had much stronger immune reactivity against ARV σC protein compared to IBV-S1. Our results indicate that ARV σC protein delivered by LAB via the IN route elicits strong mucosal immunity. A needle-free delivery approach is a convenient and cost effective method of vaccine administration, especially for respiratory infections in economic animals. Furthermore, ARV σC, a strong immunogen of ARV, may be able to serve as an immunoenhancer for other vaccines, especially avian vaccines.
has issue date	2012-07-13(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2012.04.043
bibo:pmid	22531554
has license	els-covid
sha1sum (hex)	0ea02653a85f4ad7fd8a9e0d7d80bf8e3be885c5
schema:url	https://doi.org/10.1016/j.vaccine.2012.04.043
resource representing a document's title	Avian reovirus sigma C enhances the mucosal and systemic immune responses elicited by antigen-conjugated lactic acid bacteria
has PubMed Central identifier	PMC7115360
has PubMed identifier	22531554
schema:publication	Vaccine
resource representing a document's body	covid:0ea02653a85f4ad7fd8a9e0d7d80bf8e3be885c5#body_text
is schema:about of	named entity 'serve' named entity 'spike' named entity 'pathogenic' named entity 'protein' named entity 'surfaces' named entity 'vector' named entity 'cost effective' named entity 'LAB' named entity 'assessed' named entity 'antigens' named entity 'immunity' named entity 'immune' covid:arg/0ea02653a85f4ad7fd8a9e0d7d80bf8e3be885c5 named entity 'reovirus' named entity 'immunity' named entity 'protein' named entity 'vaccination' named entity 'LAB' named entity 'ARV' named entity 'acid' named entity 'primary' named entity 'sites' named entity 'delivered' named entity 'reactivity' named entity 'IBV' named entity 'humoral' named entity 'produced' named entity 'vaccine' named entity 'Mucosal' named entity 'cell adhesion' named entity 'higher' named entity 'ARV' named entity 'protein' named entity 'lungs' named entity 'ARV' named entity 'administration' named entity 'systemic' named entity 'IBV' named entity 'spike protein' named entity 'LAB' named entity 'protein' named entity 'humoral responses' named entity 'antigens' named entity 'Mucosal surfaces' named entity 'vaccine' named entity 'Intranasal' named entity 'antigen' named entity 'vaccines' named entity 'mice' named entity 'infectious bronchitis virus' named entity 'immunization' named entity 'ARV' named entity 'immunization' named entity 'LAB' named entity 'serum' named entity 'protein' named entity 'reovirus' named entity 'cost effective' named entity 'mucosal' named entity 'Avian reovirus' named entity 'E. faecium' named entity 'Generally Recognized As Safe' named entity 'adjuvants' named entity 'probiotic' named entity 'protein binding' named entity 'LAB' named entity 'coiled-coil structure' named entity 'LAB' named entity 'BSA' named entity 'DNA vaccine' named entity 'epitopes' named entity 'serum samples' named entity 'divalent' named entity 'cloned'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software